Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

Alqahtani, S., Ozaras, R., Isakov, V., Wyles, D., Ferenci, P., Feld, J. J., Calinas, F., Gschwantler, M., Gane, E., Crawford, D., Jacobson, I. M., Dumas, E. O., King, M. and Sulkowski, M. (2017) Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. Journal of Viral Hepatitis, 24 4: 280-286. doi:10.1111/jvh.12641


Author Alqahtani, S.
Ozaras, R.
Isakov, V.
Wyles, D.
Ferenci, P.
Feld, J. J.
Calinas, F.
Gschwantler, M.
Gane, E.
Crawford, D.
Jacobson, I. M.
Dumas, E. O.
King, M.
Sulkowski, M.
Title Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin
Journal name Journal of Viral Hepatitis   Check publisher's open access policy
ISSN 1365-2893
1352-0504
Publication date 2017-04-01
Year available 2016
Sub-type Article (original research)
DOI 10.1111/jvh.12641
Open Access Status DOI
Volume 24
Issue 4
Start page 280
End page 286
Total pages 7
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2018
Language eng
Abstract High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D ± RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA
Keyword Direct-acting antiviral
Interferon-free therapy
Sustained virologic response
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 11 Apr 2017, 00:25:16 EST by Web Cron on behalf of Learning and Research Services (UQ Library)